Log in to save to my catalogue

Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and re...

Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and re...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10966995

Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and review of the literature

About this item

Full title

Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and review of the literature

Publisher

London, England: SAGE Publications

Journal title

Therapeutic advances in infectious disease, 2024-01, Vol.11

Language

English

Formats

Publication information

Publisher

London, England: SAGE Publications

More information

Scope and Contents

Contents

The use of ibrutinib, a Bruton tyrosine kinase inhibitor, has been associated with invasive fungal infections (IFIs). We describe a case of Apophysomyces infection associated with long-term use of ibrutinib for the treatment of chronic lymphocytic leukemia as well as perform a literature review of Mucormycosis infections in patients on ibrutinib. O...

Alternative Titles

Full title

Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and review of the literature

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10966995

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10966995

Other Identifiers

ISSN

2049-9361

E-ISSN

2049-937X

DOI

10.1177/20499361241241199

How to access this item